YÜKSEK DOZ ARA-C(HiDAC) PROTOKOLÜ

Kaynaklar:

1- Plunkett, W., J. O. Liliemark, T. M. Adams, et al. 1987. "Saturation of 1-beta-D-arabinofuranosylcytosine 5'-triphosphate accumulation in leukemia cells during high-dose 1-beta-D-arabinofuranosylcytosine therapy." Cancer Res 47(11):3005-3011. 

2- Sperr, W. R., M. Piribauer, F. Wimazal, et al. 2004. "A novel effective and safe consolidation for patients over 60 years with acute myeloid leukemia: intermediate dose cytarabine (2 x 1 g/m2 on days 1, 3, and 5)." Clin Cancer Res 10(12 Pt 1):3965-3971. 

3- Mayer, R. J., R. B. Davis, C. A. Schiffer, et al. 1994. "Intensive postremission chemotherapy in adults with acute myeloid leukemia. Cancer and Leukemia Group B." N.Engl.J.Med. 331(14):896-903. 

4- Bloomfield, C. D., D. Lawrence, J. C. Byrd, et al. 1998. "Frequency of prolonged remission duration after high-dose cytarabine intensification in acute myeloid leukemia varies by cytogenetic subtype." Cancer Res 58(18):4173-4179.

5- Moore, J. O., S. L. George, R. K. Dodge, et al. 2005. "Sequential multiagent chemotherapy is not superior to high-dose cytarabine alone as postremission intensification therapy for acute myeloid leukemia in adults under 60 years of age: Cancer and Leukemia Group B Study 9222." Blood. 105(9):3420-3427.

 6- Cassileth, P. A., D. P. Harrington, F. R. Appelbaum, et al. 1998. "Chemotherapy compared with autologous or allogeneic bone marrow transplantation in the management of acute myeloid leukemia in first remission." N.Engl.J.Med. 339(23):1649-1656.